1. Introduction {#sec1}
===============

Toxins are substances produced by living organisms that interfere in the physiological processes of the victim, which could be a prey, predator or a bystander. Venoms are complex mixtures of tens or hundreds of toxins and are produced in specialized organ. In venomous organisms, the toxins are actively administered into the victim by a bite or sting. In contrast, toxins produced in poisonous organisms enter the victim passively when the victim takes bite of the organism. In both situations, the victim suffers from mild to severe disturbances in various physiological processes leading to debilitation and death depending on the toxin dose. Toxins have evolved as the part of either the defensive strategy against predators or the offensive strategy to capture and subdue the prey. In poisonous organisms, as they do not actively 'hunt', toxins are produced as a deterrent against predators. Because of the importance of toxins for their survival, venomous/poisonous organisms have evolved multiple times throughout the phylogenetic tree resulting in myriads of toxins with varied structures, functions and targets in distinct physiological systems ([@bib35]). Toxinology is a multidisciplinary science, which aims in understanding various aspects of toxins including, but not limited to, the structure, function, mechanism, origin and evolution, clinical aspects and strategies to resolve the toxicity. In this review, although I focus only on toxins from venomous animals, most of these concepts fit toxins from other organisms.

Although a number of animal venoms cause mild to severe discomfort, the bites and stings from only a small number of venomous animals, such as snakes and scorpions, resulted in death and debilitation of humans ([@bib44], [@bib2], [@bib84], [@bib15], [@bib102], [@bib261], [@bib267]). Thus, most of the initial studies focused on the isolation and characterization of individual highly toxic components of these venoms and on the strategies to neutralize the pathological symptoms caused by the toxins. With the increased sophistication and high resolution in purification and characterization methods, it was possible to evaluate the toxins that could be isolated in smaller amounts. With the advent of Omics technologies, it has become much easier to complete deep transcriptomes from minimal amount of tissues, proteomics with miniscule amount of crude venoms, genomes with tiny amounts of tissues and combinations thereof. With these new technologies, we can obtain toxin profiles of venoms and complete the identification and classification all components, taken together as venomics ([@bib159], [@bib29], [@bib251], [@bib174]). This brings us to crossroads and the question 'Where do we go from here?\'. Here, I will describe my personal perspective on multidirectional and multidimensional opportunities and fascinating future in the field of toxinology ([Fig. 1](#fig1){ref-type="fig"}).Fig. 1An overview of multidirectional and multidimensional opportunities in toxinology.Fig. 1

2. Antivenom research {#sec2}
=====================

Conventional antivenoms comprise antibodies or antibody fragments derived from the plasma of larger mammals (typically horses) that have been immunized with venom(s) ([@bib148], [@bib252], [@bib83]). Quick and timely treatment of the victims through intravenous administration of antivenoms is the only accepted treatment of the severe medical emergency and concomitant multiple organ failure due to envenoming. Antivenomics helps to evaluate the quality and neutralizability of antivenoms and identifies toxins that exhibit poor antigenicity/neutralizability ([@bib159], [@bib30]). These studies indicate that despite best efforts, typical antivenoms contain only 5--46% toxin-binding antibodies ([@bib211], [@bib229], [@bib92], [@bib222]). These data along with others supporting the inherent drawbacks of antivenom use ([@bib136]) provides impetus for the development of next generation strategies to replace more than a century old technology ([@bib26], [@bib27], [@bib28]). Since the first Food and Drug Administration (FDA)-approved therapeutic monoclonal antibody (mAb) OKT3 (muromonab) in 1986 ([@bib97]), particularly human therapeutic mAbs and their fragments, have become the mainstay in the development of biologics for acute and chronic treatments of various human diseases ([@bib263], [@bib264]). The works of George P. Smith and Gregory P. Winter "for the phage display of peptides and antibodies" ([@bib199], [@bib170]) together with that of Frances H. Arnold "for the directed evolution of enzymes" ([@bib40], [@bib41], [@bib9]) laid the foundation for the development of therapeutic antibodies. All three shared the 2018 Nobel Prize in Chemistry. Phage display for panning and selection combined with directed evolution as a reliable optimization algorithm have made selection and maturation of therapeutic antibodies somewhat routine ([@bib96], [@bib217], [@bib235]). Recent improvements in antibody-expression yields and manufacturing processes have made mAbs as a cost-effective option (US\$ 20--80/g) for the treatment of various diseases ([@bib137], [@bib204], [@bib274]). Thus, there has been a dramatic rise in the use of therapeutic mAbs, with 78 mAbs approved by the FDA or the European Medicines Agency (EMA) and the annual global mAb market reached US\$100 billion in 2017 ([@bib95]). In 2018, 11 more mAbs were approved by the FDA ([@bib179], [@bib12]) and over 570 mAbs are in clinical development and this number of mAbs approved and in clinical development are growing in 2020 ([@bib115], [@bib116]). With these considerations, we proposed the production of Biosynthetic Oligoclonal Antivenom (BOA) based on recombinantly expressed oligoclonal mixtures of human mAbs or their fragments for snakebite treatment ([@bib136]). Current technologies for selection, production, and characterization, will allow the development of next generation of antivenoms against snake venom toxins ([@bib150], [@bib149], [@bib151], [@bib218]). The ability to complete high quality genomes of venomous snakes ([@bib1], [@bib276], [@bib233], [@bib202], [@bib227], [@bib246]) and to produce toxins through organoids ([@bib205]) will open avenues for BOA. Human therapeutic antibodies provide several potential advantages over conventional horse-derived antivenoms. They include compatibility with human victims, enrichment of toxin-neutralizing antibodies, consistent and reproducible quality, tailor-made mAbs and their fragments with optimal pharmacokinetics and pharmacodynamics, better safety and cross reactivity with related toxins (For details, see [@bib136]). BOA can possibly be combined with repurposed small molecule, synthetic enzyme inhibitors ([@bib22]; [@bib21], [@bib152], [@bib153], [@bib221], [@bib5]). Thus, venomics helps expanding our abilities to develop next generation antivenoms.

3. Toxin evolution {#sec3}
==================

Venoms have evolved as chemical means for prey capture and competitor and/or predator deterrence ([@bib75]). In the complexity of a food web, these indirect interactions control entire ecosystems. The sequence information obtained through proteomics, transcriptomics and genomics, in addition to providing the toxin profiles of venoms, opens new avenues in understanding the evolutionary history of toxins and in resolving these predator-prey interactions. Most accepted hypothesis for the evolutionary origins of toxin families suggests the duplication of nontoxic cognate genes expressed in other tissues, and subsequent change in tissue-specific expression (leading to venom gland expression) and neofunctionalization through modification of the structure and function. This hypothesis was supported by the structural similarity between various toxins with nontoxic proteins. With the initial protein sequence information, that evolution of protease inhibitors and ribonuclease ([@bib241], [@bib242]) and phospholipase A~2~ (PLA2) ([@bib85]) as snake venom toxins were proposed. Subsequent sequence studies have indicated that elapid and viperid PLA2s originated from pancreatic and synovial (platelet) PLA2 lineages, respectively ([@bib91], [@bib230]). With more sequence information of the toxins and their related proteins, it became clear that several other snake venom toxins originated from cognate genes encoding proteins that played roles in normal physiological functions. These included sarafotoxins/endothelins ([@bib138], [@bib139], [@bib265], [@bib269], [@bib272]), cobra venom factor ([@bib260]), natriuretic peptides ([@bib283]), nerve growth factor ([@bib50]; [@bib103], [@bib143]), vascular endothelial growth factor ([@bib140], [@bib141], [@bib271]), snake venom metalloproteases ([@bib248], [@bib93], [@bib94], [@bib10], [@bib197], [@bib198], [@bib18], [@bib109]), neurotoxin/Ly-6/lynx1 ([@bib79], [@bib69], [@bib37], [@bib162]; [@bib173]) and acetylcholinesterase ([@bib52]). Based on the protein sequences, we showed that venom prothrombin activators are structural and functional homologues of blood coagulation factors; group D prothrombin activators are similar to factor Xa ([@bib110], [@bib209]), while group C prothrombin activators are similar to factor Xa-factor Va complex ([@bib208]; [@bib210]). Some of the toxins exhibited significant diversification, while others showed minor structural and functional changes. Thus, toxins were thought to be evolved from endogenous genes regulating in normal cellular pathways ([@bib284]; [@bib71], [@bib72], [@bib125]). Recent genomes of venomous snakes ([@bib1], [@bib276], [@bib233], [@bib202], [@bib227], [@bib246]) have confirmed many of these assertions. Phylogenetic analyses of toxin families also indicate the possibility of reverse recruitment of toxin genes back to physiological roles ([@bib34]). With increasing volumes of data more such duplication, neofunctionalization, and recruitment events will be resolved.

Whole genome duplication (WGD) is considered as a potent force for evolution ([@bib281]). WGD and its impact on the emergence of evolutionary novelties and complexity, both functional and morphological, are supported by high-throughput sequence data. In vertebrate evolution, there have been two WGD or polyploidization events that are fixed over 500--600 million years ([@bib57]). In snakes, only certain class of toxin genes appear to have duplicated multiple times. For example, in cobras three-finger toxin genes have undergone multiple duplication events ([@bib1], [@bib246]; and many transcriptome and proteome studies). In contrast, in crotalids serine protease and metalloprotease genes have undergone multiple duplication events ([@bib276], [@bib233], [@bib227]). Such unusual duplications cannot be explained by WGD.

In addition to WGD, there are four mechanisms of gene duplication. In ectopic recombination, crossing over occurs at non-homologous loci leading to dramatic chromosomal rearrangement, which is generally harmful to the organism. At times, it could lead to chromosomal evolution and rapid speciation ([@bib23]). Transposable elements provide sequence similarity for this non-homologous recombination. The densities of transposable element correlate negatively with ectopic recombination, but the strength of this correlation depends on transposable element ([@bib117]). Replication slippage occurs during DNA replication and produces duplications of short (2--3 bp) genetic sequences. During replication, DNA polymerase dissociates from the DNA and replication stalls. Due to misalignment during reattachment, it copies the same DNA segment again leading to duplication ([@bib259]). Replication slippage is due to direct repetitive DNA sequences but requires only a few bases of similarity. The slippage efficiency is inversely proportional to the length of the direct repeat ([@bib259]). Retrotransposition involves reverse transcription of mRNA transcripts to DNA and their insertion in the genome as retrogenes ([@bib182]). Retrogenes usually lack introns and often contain poly-A sequences. They display changes in gene regulation leading in novel functions. Aneuploidy results in an abnormal number of chromosomes and gene dosage ([@bib17]). It is detrimental to the organism ([@bib59], [@bib183]) and is unlikely to spread through populations. I hypothesize that the ectopic recombination or a distinct new mechanism may explain duplication of toxin genes.

Duplicated genes have three different fates: (a) non-functionalization (pseudogenization) is the most likely fate of duplicated genes based on the assumption that a deleterious mutation is a much more likely outcome than a beneficial mutation (e.g., [@bib63]); (b) subfunctionalization is a process by which mutations in their regulatory or coding sequences would lead to change in their expression patterns or altered functions, respectively, of the duplicated genes. This can occur because of the relaxation of selection pressures or constraints (e.g., [@bib88]); and (c) neofunctionalization, where one paralogue acquires a new function through mutations that are beneficial for function in regulatory or coding regions, while the other paralogue retains its ancestral function. As beneficial mutations are rare events, neofunctionalization is a rarer event than non-functionalization or subfunctionalization. Mutations in noncoding regulatory regions are more common and plausible, and but mutations in gene-coding regions are rarer. Thus, it is still controversial whether neofunctionalization can indeed be a potent source of evolutionary novelties (For details, see [@bib177]). In the case of toxins genes, pseudogenization and neofunctionalization are well documented.

The mutations in the regulatory region results in the alteration of expression pattern of duplicated cognate gene from its "parent" tissue to the venom gland. This process is broadly and loosely termed as "recruitment" ([@bib72], [@bib71], [@bib74]). The molecular details in such recruitment have been identified in venom PLA2 and prothrombin activators ([Fig. 2](#fig2){ref-type="fig"}, [Fig. 3](#fig3){ref-type="fig"}, [Fig. 4](#fig4){ref-type="fig"}). Fujimi et al. analyzed several gene sequences encoding PLA2 from *Laticauda semifasciata* to determine the relationship between pancreatic and venom PLA2 genes ([@bib76], [@bib77]). They found insertions in the promoter and the first intron of group IA (venom) PLA2 gene compared with group IB" (pancreatic) PLA2 gene ([@bib76], [@bib78]) ([Fig. 2](#fig2){ref-type="fig"}). The 411-bp insert in the promoter region has two E box and one GC box binding sites and interrupts promoter region of pancreatic PLA2 gene ([Fig. 2](#fig2){ref-type="fig"}B). AG-rich inserts are \~1100 bp long in venom PLA2 genes compared to 400 bp AG-rich region of pancreatic PLA2 gene ([@bib282]) ([Fig. 2](#fig2){ref-type="fig"}A). Similarly, there was one 264 bp insertion in the promoter and 3 insertions and 2 deletions in intron 1 of the *TroD* gene (prothrombin activator gene expressed in the venom gland) compared to the *TrFX* gene (blood coagulation factor X gene expressed in the liver) ([@bib214], [@bib216]) ([Fig. 3](#fig3){ref-type="fig"}). The promoter insert disrupts the *Cis* elements controlling the liver-specific expression and contributes to expression of *TroD* gene in the venom gland. Therefore, we named this insert in *TroD* promoter region as **ve**nom **r**ecruitment/**s**witch **e**lement (*VERSE*) ([@bib216]). The AG-rich regions in second and third inserts in *TroD* intron 1 appear to act as the silencer in restricting its expression to venom glands (Described below) ([Fig. 4](#fig4){ref-type="fig"}). These two molecular evidences suggest that inserts in promoter and intron regions alter the tissue-specific expression of duplicated cognate genes from various "parent" tissues to venom gland. In these examples, the promoter inserts are distinct, but contain several *Cis* elements. Such promoter inserts that are responsible for "recruitment" be named as "*Prins*" ([Pr]{.ul}omoter [ins]{.ul}erts). In contrast, the intron inserts are AG-rich silencers. It will be interesting identify other *Prins* segments and respective silencers responsible for "recruitment" other toxin families. Genomic data will also help in identifying whether these elements are disrupted through mutations or deletions during reverse "recruitment" ([@bib34]); in both instances, one could identify the evolutionary trajectory of such cognate genes.Fig. 2Comparison of genes encoding pancreatic and venom phospholipase A2 from *Laticauda semifasciata*. **A**. Overview of gene structures of pancreatic PLA2 (AB078346) and venom PLA2s (AB062439 and AB062440). All three genes have four exons. Introns 1 of venom PLA2 genes have several insertions and some of them are AG-rich motifs. Such AG-rich motifs may be responsible for silencing their expression in no-venom gland tissues ([@bib87]). **B**. Comparison of promoter regions of pancreatic PLA2 (AM111959) and venom PLA2s (AB062439 and AB062440). The 411-bp inserts found in the venom PLA2 genes compared to pancreatic PLA2 gene. This insert has two E box and one GC box binding sites and contributes to the regulation of expression of the venom PLA2 genes. **C**. Comparison of 3′UTRs of pancreatic PLA2 (AB078346) and venom PLA2s (AB062439 and AB062440). Sequences from 3′UTRs from venom PLA2s from *Pseudonaja textilis* (AY027495) and *Bungarus multicinctus* A2 chain of β-bungarotoxin (AJ431707) are also included. Venom PLA2 genes show deletion of 234--286 bp segments. The effects of this deletion to the stability of venom PLA2 mRNAs is not known.Fig. 2Fig. 3Comparison of genes encoding liver factor X and venom prothrombin activators. **A**. Liver factor X and venom gland trocarin D genes from *Tropidechis carinatus*. **B**. Liver factor X and venom gland pseutarin C catalytic subunit from *Pseudonaja textilis*. There is a 264-bp inserts, named as *VERSE* ([VE]{.ul}nom [R]{.ul}ecruitment and [S]{.ul}witch [E]{.ul}lement) found in the promoter regions of venom prothrombin activator genes. These genes also have three insertions and two deletions in their introns 1 compared to liver factor X genes. **C**. Comparison of promoter regions of human, mouse and snake liver factor X genes with that of trocarin D. *VERSE* insert has several transcription factor-binding *cis* elements. Similar *VERSE* insert was also found in pseutarin C catalytic subunit. **D**. Identification of minimum core promoter and novel *cis* elements in *VERSE*. By systematic deletion experiments, we identified 135-bp minimum core promoter and two upregulator (Up1 and Up2) and one suppressor (Sup) elements ([@bib145]).Fig. 3Fig. 4Identification of silencer elements in venom prothrombin activator genes. **A**. Comparison of introns 1 of liver factor X (TrFX and PFX) and venom prothrombin activator genes (Trocarin D and PCCS, pseutarin C catalytic subunit). Venom gene first introns have three insertions and two deletions compared to their respective cognate genes. **B**. Identification of AG-rich silencer in insert 2. A systematic deletion studies helped us to identify AG-rich motifs as silencers of *VERSE* and *CMV* promoters (for details, see [@bib87]). **C**. Distribution of AG-rich motifs in genes encoding trocarin D and PCCS compared to the respective cognate genes. Both inserts 2 and 3 (on the minus strand) have significant number of AG-rich motifs.Fig. 4

The DNA as well as protein sequence information helps in mutation analyses within the toxin isoforms expressed by a single species, or across multiple species in a genus or even across various genera. Analysis of the cDNA sequences of *Protobothrops* (formerly, *Trimeresurus*) *flavoviridis* (habu snake) venom PLA2 enzymes indicated that the 5′ and 3′ untranslated regions are highly conserved (98% and 89%, respectively) compared to the protein-coding regions (67%) ([@bib188]). Further, mutations appeared to have accumulated at similar rates for the three positions of codons. Comparison of the gene sequences indicated that the introns are much more conserved than the protein-coding regions of exons apart from the signal peptide-coding region ([@bib180]). The nucleotide substitutions per nonsynonymous site (K~A~) are close to or larger than mutations at synonymous site (K~S~) indicating Darwinian positive selection and accelerated evolution of protein-coding regions. Similar observations in other venom PLA2s, serine proteases and C-type lectin-like proteins suggested that accelerated evolution of exons appears to be universal in toxin isoforms ([@bib186], [@bib58], [@bib190]). These accelerated mutations were thought to neofunctionalize the toxins and lead to regional variations with suitable specificity and selectivity towards their target receptor, ion channel or enzyme through positive Darwinian selection ([@bib280]; [@bib111]). Our studies showed that such accelerated mutations appear to target the molecular surface of Class I (elapid) and Class II (crotalid) venom PLA2 enzymes ([@bib125]). Interestingly, this adaptive evolution of elapid PLA2 enzymes is associated with speciation events and adaptation of the arsenal to target novel prey species ([@bib280]). Using nucleotide sequences of genes for fast-evolving toxins and human hereditary diseases, we showed that specific nucleotide sequences appear to determine point mutation rates ([@bib126]). We classified triplets (not just codons) into stable, unstable and intermediate groups. The relative distribution of stable and unstable triplets is correlated with the accelerated evolution of exons of toxin genes ([@bib126]). An analysis of gene sequences of *Sistrurus catenatus edwardsii* three-finger toxins (3FTxs) indicated that some segments in the exons changed to distinctly different segments compared to corresponding regions of the isoforms ([@bib61]). Such a "switching" of segments in exons may result in drastic alteration in the molecular surface and, hence, the molecular target of these 3FTxs. Thus, we proposed that the phenomenon of **a**ccelerated **s**egment **s**witch in **e**xons to alter **t**argeting (ASSET) may play an important role in the evolution of toxins ([@bib61]). ASSET appears to contribute to functional evolution of 3FTxs to a greater extent compared to other toxin families ([@bib62]). In snake venom serine proteases, ASSET contributes to changes in three surface segments, including the segment near the substrate binding region. Interestingly, these "exchanges" occurred only in the molecular surface of toxins not affecting the structural integrity of toxins ([@bib61], [@bib62]). Following drastic change through ASSET, accelerated point mutations probably contribute to fine-tuning of target specificity. Evolutionary fingerprint analyses of various groups of 3FTxs indicated that most residues in neurotoxic 3FTxs are under positive Darwinian selection, while κ-neurotoxins and cytotoxic 3FTxs are under negative selection ([@bib245]). The authors proposed Rapid Accumulation of Variations in Exposed Residues (RAVERS) or focal mutagenesis are responsible for the functional evolution of 3FTxs. Systematic analyses of venom disintegrin/metalloprotease genes indicated a new mechanism in the evolution through exonization and intronization ([@bib124]). In the evolution of RTS/KTS disintegrins, a new 34 bp exon (10a) is formed in intron 10. Exon 10a originated from a non-repetitive element, unlike \>90% new exons that are from repetitive elements in introns. In this case, simultaneous exonization and intronization occur within a single gene. This new mechanism introduces drastic changes to the molecular surface and alters the function of toxins ([@bib124]). Increased sequence information combined with systematic analyses will help in fine-tuning some of these mechanisms of accelerated evolution and discover several others.

4. Toxin expression {#sec4}
===================

Toxins are produced in a specialized gland and their expression is tightly regulated ([@bib118], [@bib119]; [@bib160]; [@bib258]; [@bib270]). Toxin expression is highest when the venom gland is emptied, as in the case of "milking", and it slows down when the gland is full ([@bib220], [@bib194], [@bib195], [@bib56]). It is also apparent in the columnar and squamous stature of the gland epithelial cells that is prominent in crotalid and viperid snakes. Further, the transcriptional activity in vipers shows a sharp increase on Day 3, after a 2-day lag period after milking, and is maintained until 5 days ([@bib197]). In elapid snakes, in contrast, there is no significant change in the morphology of the columnar cells before or after the stimulation of venom production ([@bib147]). The synthesis of nascent toxin mRNAs starts almost immediately (as early as 2 h) after the "milking". In situ hybridization indicated that the CTX, PLA2, and NTX mRNAs are localized only in the columnar secretory epithelial cells. Each secretory cell shows staining for all three toxins. Thus, the toxin gene expression occurs exclusively in these cells and there is no specialization for production of a specific toxin ([@bib147]). The mRNA expression encoding CTX, the most abundant toxin, increases rapidly from 0 to 24 h, while those of PLA2 and NTX increase gradually. The mRNA content for all three toxins are maintained at the elevated levels from two to eight days ([@bib147]). These changes in mRNA content correlates well with the production of respective toxins. Around eight days, once the tubular lumina of the venom glands are filled with venom, toxin synthesis slows to a minimal level ([@bib147]). Interestingly, in viperid snakes it takes about three weeks to reach this equilibrium ([@bib195]). Such a minimal toxin production status is thought to be due to the enhanced hydrostatic pressure and the amount of venom present in the lumen of the gland, which act as the main regulatory factors for the toxin synthesis ([@bib231]).

In general, toxin genes are selectively expressed in high quantities in the venom gland tissue compared to other tissues including the "parent" tissue. For example, venom group IA PLA2 gene is expressed 100--300 times (based on mRNA contents) higher in the venom gland compared with pancreas, while pancreatic group IB" PLA2 gene is expressed at similar, low levels in both tissues ([@bib78]). However, using mass spectrometry the authors could not detect group IB PLA2 in the venom of *L. semifasciata*. Prothrombin activators are also expressed in significantly higher amounts in the venom gland. The expression of trocarin D gene in the venom gland is \~30 times higher compared with that of the TrFX gene in liver ([@bib216]). Similarly, genes encoding pseutarin C catalytic and nonenzymatic subunits are specifically expressed 80- and 280-fold in the venom gland compared to blood coagulation factor X and V genes in liver, respectively ([@bib172], [@bib215]). Such a venom gland-selective expression is due to promoter and other *Cis* elements and corresponding transcription factors.

The TATA box, the first eukaryotic core promoter motif identified ([@bib155]), regulates expression of 20% genes in yeast ([@bib14]) and 24% genes in humans ([@bib273]). It is located 25--35 bp upstream of the transcription start site. Genes containing the TATA-box are more highly regulated when compared to TATA-less genes ([@bib14], [@bib11]). The first gene structure of neurotoxin, that of erabutoxin c, showed the presence of TATA box (^−33^TATAAA^−28^) in its promoter region ([@bib79]). Similarly, TATA boxes were found in the promoter regions of snake venom toxin genes, including 3FTx genes (for example, [@bib37], [@bib38], [@bib146], [@bib4]), PLA2 genes (for example, [@bib181], [@bib186], [@bib108], [@bib77], [@bib8], [@bib246]), and snake venom serine proteases (for example, [@bib104], [@bib216]). Some of these toxin genes have more than one TATA boxes ([@bib146], [@bib4], [@bib216]). The role of TATA boxes and associated other *Cis* elements in toxin expression has been characterized in PLA2 genes ([@bib108], [@bib78]), 3FTx genes ([@bib82], [@bib163], [@bib164]) and prothrombin activator (factor X subunit) gene ([@bib145]) ([Fig. 3](#fig3){ref-type="fig"}C and D). Deletion and site-directed mutation of the above promoters indicate that all these *cis* elements enhance the expression of reporter enzymes in cell culture. Although all TATA boxes are functional, one of them is the strongest promoter element.

As mentioned above, promoter inserts (*Prins*) are responsible for venom gland specific expression and the "recruitment". In the group IA PLA2 (*Laticauda semifasciata* venom LsPLA2GL1-1, LsPLA2GL2-1, and LsPLA2GL5-1) genes, there is a 411 bp insert (*Prins*) between the CCAAT box and TATA box ([@bib77]) compared to the group IB PLA2 (*L. semifasciata* 'pancreatic' LsPLA2GL16-1 and *Protobothrops elegans* pancreatic PLA2 gene) ([@bib78], [@bib43]) ([Fig. 2](#fig2){ref-type="fig"}B). This *Prins* segment has one GC box and two E boxes. The full length *Prins* enhances the expression of the reporter gene by \~7-fold ([@bib78]). By systematic deletion, the authors identified the segment −232 to −162 (containing both E boxes and GC box) that enhances expression and the segment −410 to −382 (unidentified) that strongly suppresses reporter gene transcription. Similar *Prins* segments have been found in *Naja sputatrix* (venom acidic and neutral PLA2) ([@bib108]), *Bungarus multicinctus* (A1, A2 and A8 chains of β-bungarotoxin) ([@bib45]), *Pseudonaja textilis* (venom PLA2 with pancreatic loop Pt-PLA1 and Pt-PLA2) ([@bib8]), and *Naja naja* (venom PLA2 Nana 39244 and Nana 39246) ([@bib246]) genes. Although the data is incomplete at the 5′ end of *Prins* segments in *N. sputatrix*, *B. multicinctus* and *P. textilis* venom PLA2 genes, this segment varies across different snake genera (data not shown). All *Prins* segments in venom PLA2 genes contain the GC box. Interestingly, one E box is missing in *B. multicinctus* venom PLA2 genes (data not shown). Deletion mutants of *N. sputatrix* promoter showed cell-specific regulation of expression in CHO and HepG2 cells ([@bib108]).

The PLA2 *Prins* elements enhanced expression of reporter enzymes by 3- to 7-fold ([@bib108], [@bib78]). In contrast, *VERSE* (prothrombin activator *Prins* element) enhances the expression by 19- to 49-fold in HepG2 (liver), HEK293T (kidney) and CHOK1 (ovary) cell lines ([@bib145]). It also enhanced expression in primary venom gland cells. This 264 bp *VERSE* segment has three TATA boxes (TLB), one GATA-4 and one Y-box. As TLB1 is downstream of the transcription initiation site (TIS), we concluded it as non-functional and mutated all other predicted *cis-*elements. The mutants of the GATA-4, Y-box and TLB2 show 11--51%, 42--70% and 36--62% lower reporter enzyme activity compared to the VERSE promoter, respectively. In contrast, TLB3 mutant shows 14--25% increased activity ([@bib145]). By a series of deletion mutants, one suppressor and two enhancer *cis* elements were identified ([Fig. 3](#fig3){ref-type="fig"}D). Since *VERSE* was able to drive the constitutive expression in non-venom gland cells without any specific induction, it does not contain the *cis-*elements responsible for inducible and tissue-specific expression ([@bib145]). Subsequently, we showed that AG-rich motifs which act as silencers in intron 1 ([@bib87]). These AG-rich motifs are part of two large inserts found in the venom trocarin D and pseutarin C catalytic subunit genes but not in coagulation factor X genes ([@bib214], [@bib215]) ([Fig. 4](#fig4){ref-type="fig"}). Transcription factors YY1, Sp3 and HMGB2 bind to these AG-rich motifs and silence gene expression in mammalian cells. When knockdown these transcription factors, the silencing effects of AG-rich motifs are relieved ([@bib87]). Two key features distinguish a silencer from a repressor; a classical silencer exhibits a position-independent repressive activity and it inhibits transcription from heterologous promoters ([@bib192]). As expected of true silencers, constructs containing AG-rich motifs silence heterologous cytomegalovirus (CMV) promoter ([@bib87]). AG-rich motifs are found in other toxin (3FTx, PLA2, and metalloprotease) genes but not in their physiologic counterparts ([@bib87]). Thus, AG-rich motifs contribute to regulation of expression of toxin genes.

Tissue-specific expression is determined by both *cis*-elements and transcription factors (*Trans* elements). Northern blot studies showed that CTX-2 gene was expressed in venom gland, liver, heart and muscle but not in brain ([@bib163]). Interestingly, the liver, heart and muscle predominantly express \~1 kb mRNAs, while venom gland expresses 0.5 kb mRNA. The liver also expresses a minor transcript of 0.5 kb. Further, transcription initiation and splicing also appears to be affected in various tissues. In the venom gland, there are three TISs -- the major TIS is A (+1), while two minor TISs are A (+3) and C (-2) ([@bib163]). In contrast, the major liver-specific TIS is T (-25) and other minor sites are G (-37), G (-98), C (-124) and T (-154). The liver-specific CTX-2 transcripts are lower (\~20-times) compared to the venom gland-specific CTX-2 transcripts. In CHO (Chinese Hamster Ovary) cells, although both liver and venom gland-specific TISs are functional, the major TIS is at C (-124). Further, only two CTX-2 transcripts, a full-length 408 bp transcript with 26 bp longer 5′ UTR compared to venom gland transcript and a 289 bp transcript with unspliced intron 1 that encodes truncated product with 21-residue signal peptide and a mature tripeptide ([@bib163]). The latter transcript is the major CTX mRNA in the liver. Although the authors found \~1 kb mRNA in their Northern blot experiments, no transcripts matching this size were obtained during 5′ and 3' rapid amplification of cDNA ends (RACE) analysis ([@bib163]). Thus, the TIS and splicing that affect the expression and function of the protein product, can be different in various tissues. Therefore, careful attention must be paid towards tissue-specific expression, as erroneous observations could be misleading. Systematic analyses of the transcripts along with appropriate quantitative PCR may help resolve some of these issues.

Previously, we evaluated the expression of prothrombin activator and the corresponding coagulation factor genes in the venom glands and liver ([@bib172], [@bib215], [@bib216]). Venom prothrombin genes are expressed exclusively in the venom gland but not in the liver, while corresponding coagulation factor genes are expressed exclusively in the liver but not in the venom gland. Interestingly, trocarin D promoter and the *VERSE* (a 264 bp *Prins* segment) alone induced expression of reporter enzyme in HepG2, an immortal cell line of polarized human hepatocytes ([@bib145]). Such a differential expression in the liver and cultured hepatocytes could be due to epigenetic differences the liver DNA compared to newly introduced plasmid DNA. Further, systematic studies may help in understanding the regulation of tissue-specific expression.

Although cardiotoxin and neurotoxin genes are similar, their expression levels are significantly different in the venom gland ([@bib147]). Cardiotoxins account for 60%, while neurotoxins constitute only about 3% of the total proteins in *Naja sputatrix* venom ([@bib249]). Despite high similarity, the neurotoxin promoter shows several key differences with the cardiotoxin promoter ([@bib164]). The third TATA box (−28 to −33), which is important for the enhanced expression of CTX-2, has A (-32)G mutation. Further, an Ikaros element TCCC is found only in the neurotoxin promoter. The deletion of first 52 bp from the 5' end results in a sharp eight-fold increase in reporter enzyme activity compared to the whole promoter ([@bib164]). This segment shows three single nucleotide substitutions, one nucleotide deletion and one nucleotide insertion compared to corresponding CTX promoter segment. By DNase 1 footprinting and gel retardation assays, the 23 bp segment (−678 to −655) was identified as the silencer ([@bib164]). NTX silencer, in both orientations, inhibits mouse mammary tumor virus promoter and it is 4-fold stronger than CTX silencer ([@bib164]). Systematic evaluation of the existing and newly collected data will help in enhancing our understanding of regulatory processes involved in tissue-specific expression of toxin and related cognate genes.

5. Toxin characterization {#sec5}
=========================

As mentioned above, snake venom toxins are structurally and functionally similar to cognate proteins that are expressed in various non-venom gland tissues and play important roles in normal physiological processes. Thus, cognate proteins are essential for our survival. In contrast, with some modification to the structure and accessibility toxins cause devastating debility and death in the prey or victim. Therefore, understanding the structure-function relationships and mechanisms of toxins help us understand the subtle changes that affect their pathophysiological properties.

A classic example for subtle mutation leading to dramatic change is that of sickle cell anemia. Normal red blood cells have a biconcave disc shape. Their elasticity allows them to deform and pass through capillaries. A single point mutation, GAG codon to GTG of the β-globin gene leading to E7V substitution in hemoglobin B subunits. This mutation leads to clumping of hemoglobin and altered structure of red blood cells into sickle cells. These cells attain sickle shape at low oxygen tension. Repeated sickling episodes damage the plasma membrane and reduce the elasticity. These rigid cells fail to deform as they pass through capillaries, leading to vessel occlusion (for a review, see [@bib232], [@bib32]). Their fragile nature leads to hemolysis and anemia. The sickled cells last 10--20 days, while normal cells function for 90--120 days. Sickle cell disease causes acute and chronic complications in various organ systems, and the patients suffer from severe pain, anemia, bacterial infections and stroke ([@bib213], [@bib275]). The fragile nature of sickle cells provides an adaptive advantage to the heterozygote against malaria infection. Malaria parasite *Plasmodium* fails to reproduce in the red blood cells with defective hemoglobin prematurely rupture. The hemoglobin polymerization also affects its digestion by the parasite. Thus, sickle cell trait increases people\'s chances of survival in malaria-stricken areas ([@bib144]).

Similar small sequence changes drastically affect structure and function of toxins. Endothelins and sarafotoxins (SRTX), strong vasoconstrictor peptides, are excellent examples. Endothelins are endogenous vasoconstrictor secreted by primarily in the endothelium to maintain the blood pressure ([@bib54]). Neutral endopeptidase (NEP or Neprilysin), a zinc-dependent metalloprotease cleaves two peptide bonds at the amino side of hydrophobic residues (Ser5-Leu6 followed by Asp18-Ile19) and inactivates endothelins. The removal of C-terminal Trp 21 through the second cleavage inactivates endothelins ([@bib120]). SRTXs isolated from the venom of *Atractaspis engaddensis* (side-stabbing snakes, stiletto snakes, mole vipers) are structurally and functionally similar to endothelins. Interestingly, SRTXs are resistant to inactivation by neprilysin, probably due to substitutions at both peptide bonds ([@bib236]). Several natural isoforms of SRTXs has been characterized for their function. These studies have helped in understanding subtle structure-function relationships. SRTX-d have two conserved substitutions (Ser2Thr and Val19Ile) compared to SRTX-b ([@bib16]). Although both isoforms of sarafotoxins has similar binding affinity to rabbit aorta, SRTX-d weaker vasoconstrictor potency in rabbit aortic strips and lower toxicity compared to SRTXb ([@bib16]). Unlike endothelin 1, SRTX S6c distinguishes between endothelin receptor subtypes ([@bib266]). SRTX S6c binds to ET~B~ subtype found in rat hippocampus and cerebellum with a K~i~ \~20 pM compared to ET~A~ subtype found in rat atria and aorta with a K~i~ \~4500 nM. This selectivity is most likely due to a single substitution Lys9Glu ([@bib247]). Recent crystal structure of SRTX S6b-human endothelin ET~B~ receptor complex helps in understanding the subtype selectivity of the SRTXs ([@bib106]). Unlike *A. engaddensis* SRTXs, which are 21 residues long, *A. microlepidota microlepidota* SRTXs (SRTX-m) are 24 residues, with three additional residues (DEP) at the C-terminal ([@bib90]). In comparison with SRTX-b, SRTX-m shows four orders of magnitude lower affinity for human ET~A~ and ET~B~ receptors ([@bib178]). However, both SRTX-b and SRTX-m have similar in vivo toxicity in mice ([@bib90]). Detailed studies indicated that SRTX-b and SRTX-m induce distinct hemodynamic effects in rats ([@bib166]). Although both toxins induce decrease in cardiac output, SRTX-b impairs left ventricle systolic and diastolic function, while SRTX-m induces acute right ventricular dilatation and increase in airway pressures. The truncated SRTX-m without C-terminal DEP shows similar effects as SRTX-b. Thus, the C-terminal DEP contributes significant change in the pharmacologic profile of these closely related toxins ([@bib166]). A simple tripeptide at the C-terminal changes the toxicity of SRTX-b from its vasoconstrictor effect leading to left ventricular failure to the toxicity of SRTX-m from its severe bronchoconstriction effect leading to right ventricular failure.

Akin to SRTXs, natriuretic peptides (NPs) found in snake venom (VNPs) are structural and functional homologues of physiologic NPs that play important roles in blood volume-pressure homeostasis. Human NPs, ANP, BNP and CNP, at low concentrations induce diuresis/natriuresis and at slightly higher concentrations, they also induce vasodilation. All three NPs have a conserved 17-residue NP ring structure, but they differ in their N- and C-terminal segments. Cardiomyocytes secrete ANP and BNP ([@bib55]), while vascular endothelial cells secrete CNP ([@bib244]). ANP and BNP activate NPR-A ([@bib262]), while CNP activates NPR-B ([@bib243]). The ANP/NPR-A signaling regulates vasodilation, increased renal excretion of water and electrolytes, increased endothelial permeability and inhibition of renin-angiotensin-aldosterone system and sympathetic nervous systems ([@bib223], [@bib165], [@bib19]). CNP/NPR-B signaling, on the other hand, is mainly involved in tissue remodeling, reproduction and brain functions. It also induces vasodilation and mild hypotensive effects ([@bib46]). Since the discovery of first NP from *Dendroaspis* venom (DNP; [@bib283]), VNPs are found in both elapid and viperid venoms. These VNPs exhibit distinct structural and functional attributes. Compared with ANP, DNP exhibits 60-fold higher resistance to proteolysis and 30-fold lower affinity to NPR-C binding (both involved in clearance of NPs) due to its 14-residue long C-terminal tail ([@bib283]). A chimera of CNP and DNP (ring of CNP and C-terminal tail of DNP) called CD-NP has a longer half-life ([@bib60], [@bib158]). CD-NP elicits natriuresis and diuresis through NPR-A activation using its C-terminal tail and vasodilation through NPR-B activation using its NP ring ([@bib60]). Thus, CD-NP offers the beneficial effects of both NPR-A and NPR-B signaling and avoids severe hypotension by the sole and excessive activation of NPR-A ([@bib277]). We identified and characterized a usual krait NP (KNP) from *Bungarus flaviceps* with 38-residue long C-terminal tail, which has the propensity to form an α-helix ([@bib234], [@bib237], [@bib238]). Systematic deletion studies showed that the presence of two pharmacophores that induce vasodilation through orthogonal pathways in KNP: K-Ring elevates intracellular cGMP levels through activation of NPR-A and Helix uses NO-dependent mechanisms ([@bib237]). Infusion of K-Ring shows transient vasodilation at low doses and sustained vasodilation at high doses in anesthetized rats without affecting urine volume ([@bib237], [@bib238]). As K-Ring induced only vasodilation with minimal or no diuretic effects, we used its structure-function relationships to delineate the determinants of hypotensive and diuretic functions in NPs ([@bib238]). In ANP, conserved residues (F2, M6, D7, R8, I9 and L15) within the 17-membered ring and the C-terminal tail (NSFRY) are crucial for NPR-A binding and in vivo activity ([@bib193], [@bib154], [@bib189], [@bib191]). Within K-Ring, there are several substitutions (G3D, G4R, G10S, A11T, Q12H and G14D) compared with ANP. As residues at 10, 11 and 12 positions are variable among other NPs, we hypothesized that G3D, G4R and G14D substitutions and the shorter C-terminal tail may be responsible for the distinct functional differences in the hemodynamic and diuretic effects of ANP and K-Ring. By systematic substitution, we evaluated the importance of these three residues within the NP ring and C-terminal on the hemodynamic and diuretic effects in anesthetized rats ([@bib238]). From these studies, we identified the residues responsible for hypotensive and diuretic effects in K-Ring and transferred these residues in to human ANP to create DGD-ANP, which is a diuretic peptide without vasodilatory function, and DRD-ANP, which is a vasodilatory peptide without diuretic function ([@bib238], [@bib239]). These peptides differ two or three residues from human ANP, respectively. These peptides were evaluated in conscious normal and heart failure sheep models ([@bib207]). In these instrumented sheep models, hemodynamic effects, diuretic effects and neurohormonal changes were monitored after infusion of low, medium and high doses of both these peptides. DGD-ANP induces only diuretic and natriuretic effects, while DRD-ANP induces only hypotensive effects indicating clear separation of pharmacologic profile of these peptides that differ in a single amino acid residue ([@bib207]). These first-in-class therapeutic peptides will be useful in the treatment of "Cold and Wet" and "Warm and Wet" acute decompensated heart failure patients (For details, see [@bib239], [@bib207]).

There are several other examples of toxins that have 'apparently' small change through substitution/deletion/insertion but exhibit drastic change in functional profiles. Some of these subtle changes also lead to change in disulfide pairing and hence the conformation of the protein scaffold ([@bib33], [@bib113], [@bib114], [@bib112], [@bib184], [@bib31]).

6. Impact of toxin research {#sec6}
===========================

Toxin research has contributed to both fundamental and/or applied aspects of life and biomedical sciences. I will briefly enumerate a small number of examples which could inspire future toxinologists ([Fig. 5](#fig5){ref-type="fig"}).Fig. 5Overview of impact of toxin research on various areas of life and biomedical sciences.Fig. 5

6.1. Research tools {#sec6.1}
-------------------

Highly selective interaction of toxins with their respective target receptor, ion channel or enzyme has helped in our understanding of normal physiological processes. α-Bungarotoxin, a neurotoxin isolated from *Bungarus multicinctus* venom ([@bib279]) was used as a bait to isolate the nicotinic acetylcholine receptor (nAChR) ([@bib39]), the first receptor to be isolated and the most thoroughly characterized receptors. Subsequently, α-bungarotoxin and related neurotoxins were used as ideal ligands to probe the structure and localization of various subtypes of nAChRs. Thus, α-neurotoxins have significantly contributed to our understanding on neurotransmission. Botrocetin or venom coagglutinin ([@bib212]) is a C-type lectin related protein (snaclecs) from the venom of *Bothrops* species that forms a ternary complex with von Willebrand Factor (vWF) and its platelet receptor GPIb, causing platelet agglutination and aggregation. Thus, botrocetin is an excellent tool for examining interactions between platelets and vWF, for quantification of vWF and for detecting vWF- and GPIb-related diseases ([@bib48], [@bib169]). Another snaclec, convulxin from *Crotalus durissus terrificus* venom ([@bib206]) binds to GPVI one of the two distinct platelet receptors for collagen and induces platelet aggregation ([@bib107]), while rhodocetin from *Calloselasma rhostoma* venom binds to the second collagen receptor α2β1 and inhibits platelet aggregation ([@bib65]). Thus, snaclecs are used as molecular scalpels in dissecting various stages of platelet aggregation and blood coagulation. For details on snake venom proteins used as research tools in hematology, see ([@bib6], [@bib47], [@bib49], [@bib176]). Nerve growth factor from *Agkistrodon piscivorus* venom contributed to our knowledge on cell growth regulation ([@bib50]). Stanley Cohen and Rita Levi-Montalcini received Nobel Prize in Physiology and Medicine in 1986 for their work on nerve growth factor and epidermal growth factor. For details, see [@bib171].

6.2. Gene duplication and novel libraries {#sec6.2}
-----------------------------------------

Gene duplication appears to play critical role in the multiplicity of toxin genes. Depending on the family, genera and species, distinct classes of toxin genes appear to have undergone severe duplications. For example, in elapid and viperid snakes, 3FTx genes and SVMP genes (as well as SVSP genes) have undergone multiple duplication events. In *Pseudechis* genus, PLA2 genes show severe multiple duplications. As of now, it is unclear why only certain toxin genes undergo rampant duplication. If we understand the basic mechanism of duplication, it may be possible to create novel libraries with large number of toxin genes producing extraordinary diversity of toxins. Combining this mode of library creation with accelerated evolution (natural or through error prone polymerases), it will be possible to create unimaginable large libraries of protein toxins in distinct scaffolds.

6.3. Accelerated evolution {#sec6.3}
--------------------------

Since the first discovery of accelerated evolution of PLA2 genes ([@bib188]), it has become clear that almost all toxin genes appear to show accelerated evolution (discussed above). Several theories have been proposed to explain the mechanism of accelerated mechanism. If we successfully understand the mechanism of accelerated evolution, it will aid in the development of novel libraries of protein toxins (described above).

6.4. Protein chemistry {#sec6.4}
----------------------

A large number of protein chemistry problems have been resolved through structure-function relationships of toxins. I will highlight three lessons we learnt from toxin research. While studying the structure-function relationships of snake venom PLA2s, we predicted that the myotoxic site consists of a characteristic cationic site next to a hydrophobic region ([@bib134]). This cationic site was absent in non-myotoxic PLA2s. Similar characteristic regions of cationic and hydrophobic sites were also found in non-enzymatic myotoxins isolated from snake venoms ([@bib134]). We extended this study to cytolysins isolated from phylogenetically unrelated organisms that play either offensive or defensive role ([@bib128]). These pore-forming cytotoxins showed the common features of a cationic site flanked by a hydrophobic surface ([@bib128]). When this positive charge of the cationic site is chemically modified to negative or neutral charges, the cytolytic activity of *Naja nigricollis* cardiotoxin was lost ([@bib129]). When these positive charges are retained by guanidination, cytotoxic activity was retained. Similar cytotoxic sites were identified in other toxins ([@bib42], [@bib24], [@bib25]). By systematic evaluation of over 1600 protein-protein interaction sites, we showed that proline is most commonly found in the flanking segments. We proposed that the unique chemistry of proline helps protect the integrity and conformation of the interaction sites and present the sites ([@bib131]). These hypothetical structural roles were inspired based on the RGD loop of kistrin ([@bib3]). Based on the presence of proline residues, we developed a simple predictive method to identify protein-protein interaction sites directly from the amino acid sequence ([@bib133]). Using this straightforward method, we identified the protein-protein interaction (or functional) sites of toxins ([@bib135], [@bib240]) and non-toxins ([@bib133], [@bib250], [@bib257]). As proline residues in the flanking segments enhance the protein-protein interactions, we developed a novel method to the design and development of potent peptide drugs ([@bib132]). In this universal method, incorporation of proline residues on both sides of the minimum recognition site enhance the binding ability and concomitant biological activity of the bioactive peptide by 10- to 15-fold through a non-covalent strategy. Thus, using two orthogonal methods (for details, see [@bib121]) we utilized our finding of the presence of proline residues as the common feature in the flanking segments of protein-protein interaction sites to develop a simple strategy to convert a large, unstable protein in to a small, stable and easily manipulatable bioactive peptides. Our recent studies on OH9-1 showed that this group of 3FTxs bind to the acetylcholine binding of nAChRs, same site as the classical α-neurotoxins, but with distinct set of functional site residues ([@bib89]). Alanine scan mutations of 12 residues in all three loops of OH9-1 indicated that loop II plays an important role in binding to nAChRs; both sides of loop-II β-strand interact with α1β1εδ, while only one side interacts with α3β2. Although structurally important residues for 3FTx fold are conserved in OH9-1, none of the functionally important residues found in α-neurotoxins are conserved. Thus, this group of toxins, named as Ω-neurotoxins, have evolved independently and are example of unusual convergent (functionally) evolution ([@bib89]). Similarly, Type III neurotoxins ([@bib81]) do not have the functionally important residues found in either α-or Ω-neurotoxins. Subtle changes in the α-neurotoxins leads to interface selectivity with higher affinity for the α-δ site as compared with α-ε or α-γ interfaces ([@bib255]). Recently, we characterized a novel dimeric neurotoxin, named fulditoxin from *Micrurus fulvius* (Eastern coral snake) ([@bib70]). It has a distinct dimeric quaternary structure and exhibits potent but reversible neurotoxicity in chick biventer cervices muscle. As with all classes of 3FTx neurotoxins described above binds to the acetylcholine binding pocket of nAChRs but shares none of the functional residues. Hence, we named this new group of dimeric toxins, all from *Micrurus* venoms, as Σ-neurotoxins. Thus, all these groups of 3FTx neurotoxins have evolved independently through unusual convergent functional evolution.

6.5. Protein folding {#sec6.5}
--------------------

Protein folding is one of the most intriguing fundamental questions of structural biology. Although the amino acid sequence of a protein encodes proper folding and its native three-dimensional structure, the specific determinants involved have not been clearly identified. Disulfide bonds, which are typically non-promiscuous covalent linkages between Cys residues, contribute to correct folding and conformation in disulfide-rich proteins such as toxins. We showed that this high fidelity of correct disulfide linkages in multiple disulfide toxins or protein domains is well-preserved due to a couple of key amino acid residues ([@bib113], [@bib114], [@bib184]). The globular conformation of α-conotoxins is maintained by the presence of Pro6 in intercysteine loop 1 and the C-terminal amide. Despite conserved Cys residues, χ/λ-conotoxins fold in ribbon conformation due to the replacement of Pro6 by Lys or Ser and the C-terminal amide by free carboxylic acid (For details about these conformational switches, see [@bib113], [@bib114]). Similarly, a single conserved aromatic, hydrophobic residue in intercysteine loop 3 is key to the formation of hydrophobic core and folding of EGF domains ([@bib184]). When this aromatic residue is replaced by hydrophilic residue (Y25T) leads to disruption of the hydrophobic core and EGF fold. Thus, subtle changes in key structural elements alters the disulfide linkages and hence, the disruption of the protein fold.

6.6. Targeted drug delivery {#sec6.6}
---------------------------

Toxins have high specificity and selectivity towards a specific receptor, ion channel or an enzyme. They breach various barriers in the prey to reach the target tissue or cells. The knowledge of these intricate mechanisms and the protein structures that reaches a specific site in the body will help us develop simple but sophisticated strategies to deliver 'cargoes' to the target tissue. We purified a highly selective neurotoxin, candoxin from *Bungarus candidus* venom that binds reversibly to peripheral nAChR but irreversibly to neuronal α7 nAChR ([@bib185]). Intracerebroventricular injection of candoxin causes apoptosis and death of glial cells, which express α7 nAChR ([@bib196]). Candoxin also induces apoptosis of human glial cells (Hs 683 cells) indicating it is highly specific to glial cells. A 16-mer peptide CDX designed based on the loop II (functional site) of candoxin binds to α7 nAChR as well as primary rat brain capillary endothelial cells ([@bib278]). CDX labeled micelle carrying paclitaxel extends the survival time of mice with gliobastoma. These vesicles also deliver near infrared fluorescent dye DiR to the brain ([@bib278]). Using red blood cell derived nanoparticles labeled with ^D^CDX (synthesized using all D-amino acids with reversed sequence of CDX) created a brain-targeted delivery system for doxorubicin administration ([@bib36]). Thus, based on the candoxin a nAChR-mediated brain drug delivery system was designed. 3FTxs exhibit distinct pharmacological activities by selectively binding to various targets including nAChRs, muscarinic acetylcholine receptors, GABA receptor, adrenergic receptors, α~IIb~β~3~ integrin, L-type calcium channel, acid-sensitive ion channel, acetylcholinesterase, and several blood coagulation complexes (for details, see [@bib122], [@bib73], [@bib127]). In addition, there are at least 20 classes of orphan 3FTxs whose target proteins are yet to be identified ([@bib73]). Similarly, snake venom PLA2 enzymes exhibit a wide variety of pharmacological effects including presynaptic and postsynaptic neurotoxicity, myotoxicity, hemorrhagic activity, anticoagulant and antiplatelet effects due to their specific interaction with various protein targets (For details, see [@bib130], [@bib123]). Based on the functional sites of 3FTxs, PLA2s and other toxins, the postal addresses of various tissues or cells, a number of tissue-selective delivery systems can be developed ([@bib123]). While writing this manuscript, a new drug delivery system that reduces the systemic corticosteroid exposure. By using a cysteine dense particle (CDP) based on a potassium channel blocker from scorpion venom, a highly targeted delivery of arthritis drugs to joints ([@bib51]). Thus, toxins provide ample opportunity to develop excellent drug delivery systems.

6.7. Diagnostic agents {#sec6.7}
----------------------

Based on their effects on blood coagulation and platelet aggregation, several snake venom toxins are being used in diagnosis of hereditary diseases. Some of the standard blood clotting time measurements, such as Stypven time ([@bib98]), Ecarin time ([@bib142]), dilute Russell viper venom time ([@bib253]), textarin time ([@bib254]), Taipan snake venom time ([@bib219]), and CA-1 method using carinactivase ([@bib105]), are initiated by snake venom factors. These clotting time measurements help in identifying the defects in various blood coagulation factors as well as lupus anticoagulants and oral anticoagulants. Estimation of protein C ([@bib101]), protein S ([@bib86]), Factor V Leiden ([@bib224], [@bib156]). Similarly, several snake venom proteins affecting platelet aggregation ([@bib6], [@bib47], [@bib49], [@bib176]) are used to resolve hereditary defects in platelet aggregation. For example, botrocetin is used in understanding the von Willebrand factor and glycoprotein Ib diseases ([@bib20], [@bib64]). Similarly, convulxin is used in identifying the deficiency of glycoprotein VI ([@bib187]) and in developing a highly sensitive method to study platelet aggregation in blood with low platelet counts in patients suffering from Immune thrombocytopenia (ITP) ([@bib256]). For details on the use of snake venom proteins in the hematology labs, see reviews ([@bib167], [@bib168], [@bib169], [@bib268], [@bib228], [@bib201]).

6.8. Therapeutic agents {#sec6.8}
-----------------------

The toxicity of venoms is one of the main reasons for our fascination with snakes. Over many centuries, scientists focused on understanding this toxicity and the ways to neutralize it. The discovery of bradykinin potentiating peptides in Brazilian pit viper (*Bothrops jararaca*) venom ([@bib66], [@bib67], [@bib68]) followed by the development of non-peptidic inhibitors from peptides led to the synthesis of captopril ([@bib53]). This changed the paradigm from "toxin as a villain" to "toxin as a savior". Similarly, discovery of disintegrins from *Trimeresurus gramineus* (Indian green pit viper) and *Echis carinatus* (saw scaled viper) venoms ([@bib99], [@bib100], [@bib80]) culminated in the development of potent antiplatelet agents, eptifibatide ([@bib226], [@bib203], [@bib225]) and tirofiban ([@bib13], [@bib161]). Vipegitide, a folded peptidomimetic is being developed as partial antagonist of α2β1 integrin and an antithrombotic agent based on a snaclec from *Vipera palaestinae* venom ([@bib7], [@bib175]). As described above, we are developing DRD-ANP and DGD-ANP for the personalized treatment of acute decompensated heart failure patients ([@bib239], [@bib207]). There many other laboratories have been working towards developing several novel therapeutic agents for pain, cancer and antimicrobial function. There are several reviews on various aspects of drug development from based on toxins.

7. Conclusions and prospects {#sec7}
============================

In the recent years, Omics technologies have effectively and significantly contributed in obtaining tremendous amount of information in toxinology. It will continue to provide more information in the coming years, with a much lower price tag. The database is expanding in a geometric progression and this growth showing healthy positive exponential. The data available has provided an excellent foundation and opportunities to all toxinologists. Although I have only identified four distinct directions, there are substantially more directions. In each of these directions, finding answers requires multidimensional approaches. These directions are also to an extent interconnected. As of now, we have just started scratching the surface and future expansion will lead us to more interesting questions and is limited only by our imagination. Toxinology provides excellent opportunities for fully intertwined research in fundamental and biomedical sciences. Over the last couple of decades, we have made some inroads but future holds much greater exciting and bright opportunities.

CRediT authorship contribution statement {#sec9}
========================================

**R. Manjunatha Kini:** Conceptualization, Data curation, Formal analysis, Funding acquisition, Investigation, Project administration, Writing - original draft, Writing - review & editing.

Declaration of competing interest
=================================

The authors declare that they have no known competing financial interests or personal relationships that could have appeared to influence the work reported in this paper.

I thank thousands of toxinologists who have contributed this field and their contributions helped me guide my own research career. Many of their works, I had the pleasure to read and cite. I apologize to much bigger group of scientists whose work I have not cited here due to my own knowledge limitation combined with the space limitation. I thank my teachers and mentors, who contributed directly: Professors T. Veerabasappa Gowda (University of Mysore, India), Sadaaki Iwanaga (Kyushu University, Japan) and Herbert Evans (Virginia Commonwealth University, USA). I thank Dr. Cassandra Modahl for discussions and reading the manuscript. I thank Ms. Jasmine Jia Min Lim for excellent artwork used in the graphic abstract. I acknowledge the financial support by academic grants by the 10.13039/501100001459Ministry of Education, Singapore and the 10.13039/501100001352National University of Singapore.
